



## **Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference**

November 25, 2025 at 7:30 AM EST

BOSTON--(BUSINESS WIRE)--Nov. 25, 2025-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate in a fireside chat at the 8<sup>th</sup> Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 10:25 am ET in Miami, Florida.

A live webcast of the fireside chat can be accessed under "Events & Presentations" on the Company's website at [www.verastem.com](http://www.verastem.com). A replay of the webcasts will be archived on the website for approximately 90 days following the presentation.

### **About Verastem Oncology**

Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Verastem markets AVMAPKI™ FAKZYNJA™ CO-PACK in the U.S. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition. For more information, please visit [www.verastem.com](http://www.verastem.com) and follow us on [LinkedIn](#).

View source version on [businesswire.com](http://businesswire.com): <https://www.businesswire.com/news/home/20251125239573/en/>

### **For Investor and Media Inquiries:**

Julissa Viana

Vice President, Corporate Communications,

Investor Relations & Patient Advocacy

[investors@verastem.com](mailto:investors@verastem.com) or

[media@verastem.com](mailto:media@verastem.com)

Source: Verastem Oncology